Posts Tagged ‘Boards of Pharmacy’
Colorado Pharmacy Technician Regulation Bill: Update
There are currently about 8,000 pharmacy technicians practicing in Colorado. House Bill 19-1242 (HB 1242), as discussed previously on the Baer Law Blog, requires pharmacy technicians practicing in Colorado on or after June 15, 2020, to obtain certification from the Colorado State Board of Pharmacy (Board) in the Department of Regulatory Agencies. If HB 1242…
Read MoreDistributing Compounded Drugs to Colorado Veterinarians
In late 2017, the Colorado Board of Pharmacy (Board) sent notice to all facilities registered with the Board as nonresident pharmacies. The notification addressed the distribution of medications into Colorado. The notification states, in part, the following: “Colorado law and Board rule (CRS 12-42.5-118.5 and Board Rules 21.00.20(d)) allow a nonresident pharmacy (“Pharmacy”) to distribute…
Read More2018 Arizona Opioid Epidemic Act: Pharmacist and Pharmacy Rule Changes
Earlier this year, Arizona passed the Arizona Opioid Epidemic Act (Act), a comprehensive, bipartisan bill aimed at combating the opioid epidemic. The new legislation addresses opioid treatment, opioid enforcement and oversight, opioid addiction and reversing opioid overdoses. Pharmacists and pharmacies must be aware of a few important rule changes slated to start April 26, 2018,…
Read MoreCalifornia Bilingual Prescription Label Update
How often are pharmacy prescription label instructions translated incorrectly? Should pharmacists who are fluent only in English be required to fill prescriptions with instructions in a foreign language? Who counsels the non-English speaking patients regarding their prescription(s) and/or side effects of the medication(s)? Who is ultimately liable for the incorrect translated instructions in the event…
Read MoreCountdown to October 6, 2014: Hydrocodone Containing Product Reclassification
As discussed previously here on the Baer Law Blog, after more than a decade of debate, hydrocodone containing products (HCPs) are being reclassified from Schedule III to the more restrictive Schedule II controlled substances category starting October 6, 2014. HCPs are the most prescribed drug in the United States, second only to levothyroxine, a thyroid…
Read More